CT 및 MRI 조영제 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 모달리티별, 제품별, 투여 경로별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

CT And MRI Contrast Agents Market Trends:

The global CT and MRI contrast agents market size was estimated at USD 6.22 billion in 2024 and is anticipated to grow at a CAGR of 7.81% from 2025 to 2030. The increasing demand for iodinated contrast media, the rising burden of chronic disorders, and the rising focus of government bodies on improving diagnostic infrastructure are anticipated to support the market growth. Several government authorities are undertaking initiatives to increase access to medical imaging such as CT and MRI.

For instance, in March 2024, data published by the UK government revealed that the Community Diagnostic Centre (CDC) program has provided over 7 million diagnostic tests, checks, and scans across England since its launch in July 2021. This initiative is supported by an investment of USD 2.45 billion, marking the most significant financial commitment to CT and MRI capacity in the history of the NHS. Around 155 centres are operational in England, and the government is focused on opening 160 centres by March 2025. This growing focus on expanding diagnostic facilities is expected to drive market growth.

The increasing prevalence of chronic conditions, such as cardiovascular and neurological disorders, is expected to drive the demand for CT and MRI contrast agents. These agents are crucial in neurological imaging as they enhance the visibility of brain structures and abnormalities. Similarly, in cardiac imaging, these agents aid in diagnosing and assessing heart disease. According to a study published by ScienceDirect in January 2023, approximately 50% of CT scans and 40% of MRI scans utilize iodine or gadolinium-based contrast agents to improve image contrast and enhance diagnostics. This figure rises to 60% for neurological examinations. As a result, the growing prevalence of chronic disorders is expected to increase the demand for CT and MRI contrast agents in the coming years.

The below graph and table highlight the increasing incidence of brain tumors across the globe. It shows that the majority of individuals with brain and CNS cancer are in Asia. Around 2,58,996 new brain and CNS cancer cases are anticipated in Asia in 2045. Thus, the growing incidence of neurological conditions such as brain tumors across various regions such as Asia, Europe, Oceania, North America, and Africa is anticipated to boost the demand for CT and MRI contrast agents.

In addition, the increasing demand for iodinated contrast media is projected to propel the market growth. In 2022, the U.S. FDA reported the shortage of iodinated contrast media. In addition, in August 2023, a study led by University of Missouri School of Medicine neurologist Dr. Adnan Qureshi found that the iodinated contrast dye shortage had a significant impact on the assessment of stroke patients at hospitals across the U.S. This shortage resulted in a decline in CT procedures. This shortage, coupled with the rising prevalence of infectious diseases, has prompted manufacturers to enhance production capacities.

For instance, GE Healthcare invested USD 80 million in November 2022 to expand iodinated contrast media production at its site in Norway, aiming to meet global demand. Iohexol and iodixanol APIs are crucial in GE's iodinated contrast media, used in over 100 million patient doses annually-equivalent to three procedures every second. With investments and new production lines, the production capacity is anticipated to increase by 30 million doses per year by 2025, highlighting the growing demand for these essential molecules.

Market Concentration & Characteristics

The CT and MRI contrast agents industry is in a moderate growth stage, driven by the rising prevalence of chronic disorders, growing production capacities, and increasing healthcare investments.

The CT and MRI contrast agents market is experiencing a significant surge in innovation. Key developments include enhanced formulations for safer and more effective agents, using nanotechnology for more precise imaging, and introducing biodegradable agents that minimize environmental impact. For instance, in April 2023, GE HealthCare launched Pixxoscan (gadobutrol), a gadolinium-based MRI contrast agent featuring eco-friendly +PLUSPAK plastic packaging that reduces costs, minimizes environmental impact, and enhances safety.

Regulations are crucial in the CT and MRI contrast agents market, ensuring patient safety and quality standards. Regulatory bodies such as the U.S. FDA, the European Union, and other regional authorities regulate clinical trials and marketing authorization for CT and MRI contrast agents. For instance, in June 2023, the FDA approved the iodine-based contrast agent iopromide injection (Ultravist) for intravenous and intraarterial contrast-enhanced mammography. Ultravist is also used in CT procedures. Such approvals are anticipated to drive the CT and MRI contrast agents industry over the forecast period.

Companies in the CT and MRI contrast agents industry are introducing innovative substitute products. For instance, in October 2024, GE Healthcare announced the completion of its Phase I clinical development for a manganese-based macrocyclic MRI contrast agent. If authorized, this agent could act as an alternative to gadolinium-based contrast agents and mitigate the environmental impact of gadolinium excreted by patients.

The industry is undergoing considerable regional growth as major players aim to enhance their global presence. For instance, in October 2022, GE Healthcare's Pharmaceutical Diagnostics division announced a long-term agreement with Chilean mining company Sociedad Quimica y Minera de Chile S.A. (SQM), to ensure a stable supply of iodine, a crucial component for contrast media used in X-ray and CT procedures worldwide.

Global CT And MRI Contrast Agents Market Report Segmentation

This report forecasts revenue & volume growth of the CT and MRI Contrast Agents market and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global agrochemicals market report based on product, modality, application, route of administration, end-use, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Gadolinium-based Contrast Media
• Iodinated Contrast Media
• Modality Outlook (Revenue, USD Million, 2018 - 2030)
• Magnetic Resonance Imaging
  • Elucirem/ Vueway
  • Dotarem
  • ProHance
  • MultiHance
  • Gadovist
  • Eovist / Primovist
  • Clariscan
  • Other Generics
• X-ray/ Computed Tomography
  • Optiray
  • ISOVUE
  • Ultravist
  • Omnipaque
  • Visipaque
  • Other Generics
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Cardiovascular Disorders
• Neurological Disorders
• Gastrointestinal Disorders
• Cancer
• Nephrological Disorders
• Musculoskeletal Disorders
• Others
• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
• Intravenous
• Oral Route
• Rectal Route
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Diagnostic Imaging Centers
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of Primary Research
  • 1.5.1. Data for Primary Interviews in North America
  • 1.5.2. Data for Primary Interviews in Europe
  • 1.5.3. Data for Primary Interviews in Asia Pacific
  • 1.5.4. Data for Primary Interviews in Latin America
  • 1.5.5. Data for Primary Interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity Flow Approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume Price Analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. CT and MRI Contrast Agents Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising Prevalence of Chronic Disorders
    • 3.2.1.2. Technological Advancements
    • 3.2.1.3. Increasing Demand for Medical Imaging
    • 3.2.1.4. Rising Investment in Research & Development
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Side effects associated with contrast agents
  • 3.2.3. Market Opportunities Analysis
    • 3.2.3.1. Growing number of clinical trials
    • 3.2.3.2. Expansion opportunities in emerging markets
  • 3.2.4. Market Challenges Analysis
    • 3.2.4.1. Rising competition
• 3.3. CT and MRI Contrast Agents Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining Power of the Suppliers
    • 3.3.1.2. Bargaining Power of the Buyers
    • 3.3.1.3. Threats of Substitution
    • 3.3.1.4. Threats From New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological Landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal Landscape

Chapter 4. CT and MRI Contrast Agents Market: Product Estimates & Trend Analysis

• 4.1. Definitions and Scope
• 4.2. Product Market Share, 2018 & 2030
• 4.3. Segment Dashboard
• 4.4. CT and MRI Contrast Agents Market by Product Outlook
• 4.5. Market Size & Forecasts and Trend Analysis, 2025 to 2030 for the following:
  • 4.5.1. Gadolinium-based Contrast Media
    • 4.5.1.1. Gadolinium-based contrast media market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.2. Iodinated Contrast Media
    • 4.5.2.1. Iodinated contrast media market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. CT and MRI Contrast Media Market: Modality Estimates & Trend Analysis

• 5.1. Definitions and Scope
• 5.2. Modality Market Share, 2024 & 2030
• 5.3. Segment Dashboard
• 5.4. CT and MRI Contrast Media Market by Modality Outlook
• 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5.1. Magnetic Resonance Imaging
    • 5.5.1.1. Magnetic resonance imaging market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.1.2. Elucirem/Vueway
      • 5.5.1.2.1. Elucirem/Vueway market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.1.3. Dotarem
      • 5.5.1.3.1. Dotarem market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.1.4. ProHance
      • 5.5.1.4.1. ProHance market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.1.5. MultiHance
      • 5.5.1.5.1. MultiHance market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.1.6. Gadovist
      • 5.5.1.6.1. Gadovist market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.1.7. Eovist / Primovist
      • 5.5.1.7.1. Eovist / Primovist market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.1.8. Clariscan
      • 5.5.1.8.1. Clariscan market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.1.9. Other Generics
      • 5.5.1.9.1. Other generics market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5.2. X-ray/Computed Tomography
    • 5.5.2.1. X-ray/computed tomography market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.2.2. Optiray
      • 5.5.2.2.1. Optiray market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.2.3. ISOVUE
      • 5.5.2.3.1. ISOVUE market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.2.4. Ultravist
      • 5.5.2.4.1. Ultravist market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.2.5. Omnipaque
      • 5.5.2.5.1. Omnipaque market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.2.6. Visipaque
      • 5.5.2.6.1. Visipaque market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.2.7. Other Generics
      • 5.5.2.7.1. Other generics market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. CT and MRI Contrast Media Market: Application Estimates & Trend Analysis

• 6.1. Definitions and Scope
• 6.2. Application Market Share, 2024 & 2030
• 6.3. Segment Dashboard
• 6.4. CT and MRI Contrast Media Market by Application Outlook
• 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5.1. Cardiovascular Disorders
    • 6.5.1.1. Cardiovascular disorders market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.2. Neurological Disorders
    • 6.5.2.1. Neurological disorders market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.3. Gastrointestinal Disorders
    • 6.5.3.1. Gastrointestinal disorders market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.4. Cancer
    • 6.5.4.1. Cancer market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.5. Nephrological Disorders
    • 6.5.5.1. Nephrological disorders market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.6. Musculoskeletal Disorders
    • 6.5.6.1. Musculoskeletal disorders market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.7. Others
    • 6.5.7.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. CT and MRI Contrast Media Market: Route of Administration Estimates & Trend Analysis

• 7.1. Definitions and Scope
• 7.2. Route of Administration Market Share, 2024 & 2030
• 7.3. Segment Dashboard
• 7.4. CT and MRI Contrast Media Market by Route of Administration Outlook
• 7.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5.1. Intravenous
    • 7.5.1.1. Intravenous contrast media market estimates and forecast 2018 to 2030 (USD Million)
  • 7.5.2. Oral Contrast Media
    • 7.5.2.1. Oral contrast media market estimates and forecast 2018 to 2030 (USD Million)
  • 7.5.3. Rectal
    • 7.5.3.1. Rectal contrast media market estimates and forecast 2018 to 2030 (USD Million)

Chapter 8. CT and MRI Contrast Media Market: End Use Estimates & Trend Analysis

• 8.1. Definitions and Scope
• 8.2. End Use Market Share, 2024 & 2030
• 8.3. Segment Dashboard
• 8.4. CT and MRI Contrast Media Market by End Use Outlook
• 8.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.5.1. Hospitals
    • 8.5.1.1. Hospitals market estimates and forecast 2018 to 2030 (USD Million)
  • 8.5.2. Diagnostic Imaging Centers
    • 8.5.2.1. Diagnostic imaging centers market estimates and forecast 2018 to 2030 (USD Million)
  • 8.5.3. Others
    • 8.5.3.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 9. CT and MRI Contrast Agents Market: Regional Estimates & Trend Analysis, By Product

• 9.1. Regional market share analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Regional Market Share and Leading Players, 2024
  • 9.4.1. North America
  • 9.4.2. Europe
  • 9.4.3. Asia Pacific
  • 9.4.4. Latin America
  • 9.4.5. Middle East and Africa
• 9.5. Market Size & Forecasts, and Trend Analysis, 2018 to 2030
• 9.6. CT and MRI Contrast Agents Market Share, By Region, 2024 & 2030 (USD Million)
• 9.7. North America
  • 9.7.1. North America CT and MRI Contrast Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7.2. U.S.
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Competitive Scenario
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. Reimbursement Scenario
    • 9.7.2.5. U.S. Market Estimates and Forecasts, 2018 - 2030
  • 9.7.3. Canada
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Competitive Scenario
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. Reimbursement Scenario
    • 9.7.3.5. Canada Market Estimates and Forecasts, 2018 - 2030
  • 9.7.4. Mexico
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Competitive Scenario
    • 9.7.4.3. Regulatory Framework
    • 9.7.4.4. Reimbursement Scenario
    • 9.7.4.5. Mexico Market Estimates and Forecasts, 2018 - 2030
• 9.8. Europe
  • 9.8.1. Europe CT and MRI Contrast Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8.2. UK
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Competitive Scenario
    • 9.8.2.3. Regulatory Framework
    • 9.8.2.4. Reimbursement Scenario
    • 9.8.2.5. UK Market Estimates and Forecasts, 2018 - 2030
  • 9.8.3. Germany
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Competitive Scenario
    • 9.8.3.3. Regulatory Framework
    • 9.8.3.4. Reimbursement Scenario
    • 9.8.3.5. Germany Market Estimates and Forecasts, 2018 - 2030
  • 9.8.4. France
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Competitive Scenario
    • 9.8.4.3. Regulatory Framework
    • 9.8.4.4. Reimbursement Scenario
    • 9.8.4.5. France Market Estimates and Forecasts, 2018 - 2030
  • 9.8.5. Italy
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Competitive Scenario
    • 9.8.5.3. Regulatory Framework
    • 9.8.5.4. Reimbursement Scenario
    • 9.8.5.5. Italy Market Estimates and Forecasts, 2018 - 2030
  • 9.8.6. Spain
    • 9.8.6.1. Key Country Dynamics
    • 9.8.6.2. Competitive Scenario
    • 9.8.6.3. Regulatory Framework
    • 9.8.6.4. Reimbursement Scenario
    • 9.8.6.5. Spain Market Estimates and Forecasts, 2018 - 2030
  • 9.8.7. Denmark
    • 9.8.7.1. Key Country Dynamics
    • 9.8.7.2. Competitive Scenario
    • 9.8.7.3. Regulatory Framework
    • 9.8.7.4. Reimbursement Scenario
    • 9.8.7.5. Denmark Market Estimates and Forecasts, 2018 - 2030
  • 9.8.8. Sweden
    • 9.8.8.1. Key Country Dynamics
    • 9.8.8.2. Competitive Scenario
    • 9.8.8.3. Regulatory Framework
    • 9.8.8.4. Reimbursement Scenario
    • 9.8.8.5. Sweden Market Estimates and Forecasts, 2018 - 2030
  • 9.8.9. Norway
    • 9.8.9.1. Key Country Dynamics
    • 9.8.9.2. Competitive Scenario
    • 9.8.9.3. Regulatory Framework
    • 9.8.9.4. Reimbursement Scenario
    • 9.8.9.5. Norway Market Estimates and Forecasts, 2018 - 2030
• 9.9. Asia Pacific
  • 9.9.1. Asia Pacific CT and MRI Contrast Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.9.2. China
    • 9.9.2.1. Key Country Dynamics
    • 9.9.2.2. Competitive Scenario
    • 9.9.2.3. Regulatory Framework
    • 9.9.2.4. Reimbursement Scenario
    • 9.9.2.5. China Market Estimates and Forecasts, 2018 - 2030
  • 9.9.3. India
    • 9.9.3.1. Key Country Dynamics
    • 9.9.3.2. Competitive Scenario
    • 9.9.3.3. Regulatory Framework
    • 9.9.3.4. Reimbursement Scenario
    • 9.9.3.5. India Market Estimates and Forecasts, 2018 - 2030
  • 9.9.4. Japan
    • 9.9.4.1. Key Country Dynamics
    • 9.9.4.2. Competitive Scenario
    • 9.9.4.3. Regulatory Framework
    • 9.9.4.4. Reimbursement Scenario
    • 9.9.4.5. Japan Market Estimates and Forecasts, 2018 - 2030
  • 9.9.5. South Korea
    • 9.9.5.1. Key Country Dynamics
    • 9.9.5.2. Competitive Scenario
    • 9.9.5.3. Regulatory Framework
    • 9.9.5.4. Reimbursement Scenario
    • 9.9.5.5. South Korea Market Estimates and Forecasts, 2018 - 2030
  • 9.9.6. Thailand
    • 9.9.6.1. Key Country Dynamics
    • 9.9.6.2. Competitive Scenario
    • 9.9.6.3. Regulatory Framework
    • 9.9.6.4. Reimbursement Scenario
    • 9.9.6.5. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 9.9.7. Australia
    • 9.9.7.1. Key Country Dynamics
    • 9.9.7.2. Competitive Scenario
    • 9.9.7.3. Regulatory Framework
    • 9.9.7.4. Reimbursement Scenario
    • 9.9.7.5. Australia Market Estimates and Forecasts, 2018 - 2030
• 9.10. Latin America
  • 9.10.1. Latin America CT and MRI Contrast Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.10.2. Brazil
    • 9.10.2.1. Key Country Dynamics
    • 9.10.2.2. Competitive Scenario
    • 9.10.2.3. Regulatory Framework
    • 9.10.2.4. Reimbursement Scenario
    • 9.10.2.5. Brazil Market Estimates and Forecasts, 2018 - 2030
  • 9.10.3. Argentina
    • 9.10.3.1. Key Country Dynamics
    • 9.10.3.2. Competitive Scenario
    • 9.10.3.3. Regulatory Framework
    • 9.10.3.4. Reimbursement Scenario
    • 9.10.3.5. Argentina Market Estimates and Forecasts, 2018 - 2030
• 9.11. Middle East and Africa
  • 9.11.1. Middle East and Africa CT and MRI Contrast Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.11.2. South Africa
    • 9.11.2.1. Key Country Dynamics
    • 9.11.2.2. Competitive Scenario
    • 9.11.2.3. Regulatory Framework
    • 9.11.2.4. Reimbursement Scenario
    • 9.11.2.5. South Africa Market Estimates and Forecasts, 2018 - 2030
  • 9.11.3. Saudi Arabia
    • 9.11.3.1. Key Country Dynamics
    • 9.11.3.2. Competitive Scenario
    • 9.11.3.3. Regulatory Framework
    • 9.11.3.4. Reimbursement Scenario
    • 9.11.3.5. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
  • 9.11.4. UAE
    • 9.11.4.1. Key Country Dynamics
    • 9.11.4.2. Competitive Scenario
    • 9.11.4.3. Regulatory Framework
    • 9.11.4.4. Reimbursement Scenario
    • 9.11.4.5. UAE Market Estimates and Forecasts, 2018 - 2030
  • 9.11.5. Kuwait
    • 9.11.5.1. Key Country Dynamics
    • 9.11.5.2. Competitive Scenario
    • 9.11.5.3. Regulatory Framework
    • 9.11.5.4. Reimbursement Scenario
    • 9.11.5.5. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors
  • 10.3.2. Key Company Market Share Analysis, 2024
• 10.4. Key Company Profiles
  • 10.4.1. Bayer
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. GE Healthcare
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Guerbet
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Bracco Diagnostics Inc
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Fresenius Kabi
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives